Skip to content

Bio-Rad Laboratories, Inc. BIO.B Equity method investments (Note 11)

Equity method investments (Note 11) at other companies

Abbott logo
AbbottABT
Charles River Laboratories logo
Charles River LaboratoriesCRL
Quest Diagnostics logo
Quest DiagnosticsDGX

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EquityMethodInvestments.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s equity method investments (note 11).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s equity method investments (note 11)?
Bio-Rad Laboratories, Inc. (BIO.B) reported equity method investments (note 11) of $27.2M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s equity method investments (note 11) changed year-over-year?
Bio-Rad Laboratories, Inc.'s equity method investments (note 11) decreased by 15.0% year-over-year, from $32M to $27.2M.
What is the long-term trend for Bio-Rad Laboratories, Inc.'s equity method investments (note 11)?
Over 3 years (2020 to 2025), Bio-Rad Laboratories, Inc.'s equity method investments (note 11) has grown at a -1.3% compound annual growth rate (CAGR), from $38.4M to $36.9M.